Connect with us

Published

on

Nigel Farage has refused to criticise Donald Trump for claiming pregnant women who take paracetamol risk causing autism in their child – saying “science is never settled”.

The Reform UK leader was asked by Nick Ferrari on LBC whether the US president was right to make the link, which UK health officials have discredited.

Politics latest: Pensions triple lock to stay, says minister

He replied: “I have no idea … you know, we were told thalidomide was a very safe drug and it wasn’t. Who knows, Nick, I don’t know.”

Mr Farage, who is a friend of Mr Trump, said the president has a “particular thing about autism – I think because there’s been some in his family, he feels it very personally”.

Asked if he would side with medical experts who have said there is no evidence for the link, Mr Farage said: “I wouldn’t, when it comes to science, I don’t side with anybody.

“I don’t side with anybody, you know, because, because science is never settled, and we should remember that.”

Pressed again on whether it was irresponsible to make that link as US president, Mr Farage replied: “That’s an opinion he’s got. It’s not one that I necessarily share. But I mean, honestly, I’ve no idea.”

On Monday, the US president claimed there had been a “meteoric rise” in cases of autism and suggested the use of Tylenol – an American-branded version of paracetamol – during pregnancy is a potential cause.

UK health experts and officials have pushed back hard on the claim, saying there is “no evidence” for it – including Health Secretary Wes Streeting, who said that “I trust doctors over President Trump, frankly, on this”.

Speaking on ITV’s Lorraine, Mr Streeting said: “I’ve just got to be really clear about this: there is no evidence to link the use of paracetamol by pregnant women to autism in their children. None.”

The health secretary then referenced a major study in Sweden last year that involved 2.4 million children, adding it “did not uphold those claims”.

He added: “I would just say to people watching, don’t pay any attention whatsoever to what Donald Trump says about medicine.

“In fact, don’t take even take my word for it, as a politician – listen to British doctors, British scientists, the NHS.”

The health secretary also took aim at Mr Farage over his failure to criticise the US president, saying he had “no idea and no backbone”.

Read more:
Here’s what the evidence says about Trump’s paracetamol claims
Davey warns Farage wants to turn Britain into ‘Trump’s America’

He referred to a separate controversy in which Dr Aseem Malhotra, a vaccine-sceptic doctor, told the Reform Party conference that the COVID vaccine gave the royal family cancer.

“Anti-science, anti-reason, anti-NHS,” Mr Streeting said.

A spokesperson for Reform UK said: “Dr Aseem Malhotra is a guest speaker with his own opinions who has an advisory role in the US government. Reform UK does not endorse what he said but does believe in free speech.”

The Liberal Democrats also criticised Mr Farage, accusing him of wanting to impose Mr Trump’s “dangerous anti-science agenda here in the UK”.

A spokeswoman said: “Peddling this kind of nonsense is irresponsible and wrong.

“It seems Farage would rather see pregnant women suffer in pain than stand up to his idol Donald Trump.”

Continue Reading

Politics

Prospective CFTC chair addresses DeFi regulation at nomination hearing

Published

on

By

Prospective CFTC chair addresses DeFi regulation at nomination hearing

Michael Selig, who serves as chief counsel for the crypto task force at the US Securities and Exchange Commission, faced questions from lawmakers on the Senate Agriculture Committee for his nomination to be the next chair of the Commodity Futures Trading Commission.

On Wednesday, Selig appeared before the committee and addressed questions and concerns from lawmakers on both sides of the aisle regarding his potential conflicts of interest, policy views and experience as the next CFTC chair, succeeding Caroline Pham.

Government, Senate, SEC, CFTC, United States
Michael Selig addressing lawmakers on Wednesday’s confirmation hearing. Source: US Senate Agriculture Committee

In his opening statement, Selig said he had advised a wide range of market participants, including digital asset companies, and warned against the agency taking a regulation-by-enforcement approach, stating that it would drive companies offshore. 

“We’re at a unique moment in the history of our financial markets,” said Selig. “A wide range of new technologies, products, and platforms are emerging […] the digital asset economy alone has grown from a mere curiosity to a nearly $4 trillion market.”

The confirmation of Selig, whom US President Donald Trump nominated to chair the CFTC following the removal of his first pick, Brian Quintenz, is expected to head for a vote soon. According to the Senate calendar, the Agriculture Committee is scheduled to discuss his nomination on Thursday.

Addressing DeFi, crypto enforcement, roles of agency

The prospective CFTC chair responded to questions from the committee chair, Senator John Boozman, who advocated for the agency to take a leading role in regulating spot digital commodity markets. The senator’s remarks came as the committee is expected to consider a market structure bill that would give the CFTC more authority to regulate crypto.

“The CFTC, and only the CFTC, should regulate the trading of digital commodities,” said Boozman. 

Related: SEC’s ‘future-proofing’ push to shape how much freedom crypto enjoys after Trump

The Arkansas senator questioned Selig about his potential approach to decentralized finance if he were to be confirmed, an issue that reportedly divided many lawmakers on the market structure bill. 

“When we’re thinking about DeFi, it’s something of a buzzword, but really we should be looking to onchain markets and onchain applications and thinking about the features of these applications as well as where there’s an actual intermediary involved […]” said Selig.

He added that it was “vitally important that we have a cop on the beat” in response to a question on regulating crypto, specifically spot digital asset commodity markets.